ARPA-H Just Bet $144 Million That Aging Is a Treatable Condition — And the Funding Model Is as Radical as the Science

Cambrian BioPharma received $30.8 million to test a next-generation rapamycin analog on healthy older adults. Not cancer patients. Not diabetics. Healthy people — because the target is aging itself, and the federal government just decided that's worth $144 million in milestone-contingent contracts.

The Advanced Research Projects Agency for Health announced its PROSPR program — PROactive Solutions for Prolonging Resilience — in February 2026, awarding contracts to seven research teams across universities and biotech companies. ARPA-H Director Alicia Jackson called it "a tectonic shift in how we study healthy aging." The framing matters: not how we treat diseases of aging, but how we treat aging as the upstream condition that produces those diseases.

For the research community, the scientific ambition is significant. But the funding structure may be even more consequential. PROSPR doesn't use grants. It uses contracts — performance-contingent agreements where money flows only when teams hit aggressive milestones. That distinction reshapes incentives, timelines, and strategy for every institution involved.

Seven Teams, Three Approaches, One Question

The PROSPR portfolio splits into three categories: data integration teams building the measurement infrastructure, university groups running clinical trials, and biotech companies testing drug candidates. Together, they're trying to answer a single question: can you detect aging early enough to intervene, and can interventions measurably extend healthspan?

Stanford University is building the measurement layer. Their team will harmonize existing health datasets from multiple institutions to generate a "PROSPR-IC score" — a composite healthspan metric — then validate it through a one-year lifestyle intervention trial using digital health assessment technology. The goal isn't to test a drug but to build the scoring system that every other team needs to define success.

Columbia University Mailman School of Public Health takes a complementary approach, mining data from completed intervention trials to identify biomarkers that actually respond to treatment. If Stanford is building the thermometer, Columbia is figuring out what temperature readings mean.

University of Texas Health Science Center at San Antonio is the most ambitious clinical play among the academic teams. They're establishing regulatory pathways for aging therapeutics through Phase 3 trials that repurpose three FDA-approved drugs for healthspan extension. Repurposing existing drugs sidesteps years of safety testing — a deliberate shortcut that ARPA-H built into the program design.

University of Rochester and Brown University are running a joint trial targeting the "dark genome" — retrotransposons, virus-like DNA sequences that become increasingly active as cellular defenses weaken with age. Their trial will test Censavudine (TPN-101), an HIV drug that inhibits the reverse transcriptase activity driving retrotransposon activation, in at least 200 healthy adults aged 60-65 over 48 weeks. As Brown's John Sedivy explained, "the goal is not to treat diseases, but to treat aging itself."

On the biotech side, Cambrian BioPharma's $30.8 million contract funds trials of a next-generation rapamycin analog designed to selectively inhibit mTORC1 — the metabolic pathway most consistently linked to aging in preclinical research. Linnaeus Therapeutics received $22 million to advance LNS8801, a compound targeting the G protein-coupled estrogen receptor (GPER) that showed unexpected age-related benefits in oncology trials involving over 100 cancer patients. Apollo Alpha is testing an oral compound targeting energy metabolism and inflammation.

Why Contracts Instead of Grants

The distinction between a grant and a contract sounds bureaucratic. It isn't. Grants give researchers money to pursue a defined area of inquiry with significant latitude over methodology and timeline. Contracts pay for specific deliverables on specific schedules. If you miss a milestone, the money stops.

ARPA-H chose contracts deliberately. The program structure requires teams to hit aggressive research milestones to receive continued funding, with each contract varying in amount per awardee based on the scope and cost of their deliverables. This is the DARPA model applied to health research: high risk, high accountability, and no patience for incremental progress.

For university teams, the contract structure creates both opportunities and challenges. The upside is substantial funding — up to $22 million per team — with multi-year horizons. The downside is that missing milestones doesn't just mean a bad progress report; it means the contract ends. Principal investigators accustomed to the relative flexibility of R01 or R21 grant mechanisms will find PROSPR's performance requirements unfamiliar and demanding.

For biotech companies, the contract model is more natural. Cambrian, Linnaeus, and Apollo Alpha are accustomed to milestone-driven funding from venture capital. What's unusual is the source — federal money carrying federal reporting requirements — combined with the mandate to measure healthspan rather than disease-specific endpoints.

The 1-to-3-Year Bet

The most radical aspect of PROSPR isn't the money or the mechanism. It's the timeline. Traditional longevity research faces a fundamental measurement problem: if you want to prove that an intervention extends healthy lifespan, you need to follow people for decades. Clinical trials that long are prohibitively expensive and nearly impossible to manage.

PROSPR sidesteps this by using biomarkers as surrogate endpoints. Instead of waiting 20 years to see if trial participants live longer, the teams will measure molecular, physiological, and functional markers of aging over one to three years. Stanford's healthspan score and Columbia's biomarker work exist precisely to create the measurement infrastructure that makes short trials meaningful.

This is a calculated bet. If the biomarkers prove to be reliable proxies for healthspan — if a one-year improvement in biological aging markers actually predicts longer, healthier lives — then PROSPR will have established the regulatory and scientific framework for an entirely new category of medicine. If the biomarkers don't correlate with long-term outcomes, the program will have spent $144 million on trials that can't answer the question they were designed to ask.

The scientific community is watching carefully. As the Fight Aging! Foundation noted, human testing across multiple approaches is "the most important outcome" for establishing aging treatment as a legitimate medical field. PROSPR is the first large-scale, federally funded effort to run those trials simultaneously.

What This Means for the Research Community

PROSPR is not an open solicitation. The seven teams were selected, and the contracts are awarded. But the program's implications extend far beyond its immediate participants.

For aging researchers: PROSPR legitimizes healthspan extension as a fundable research category at the federal level. If the program produces publishable results from its clinical trials, expect follow-on funding opportunities from both ARPA-H and potentially NIH. Researchers building aging biomarker capabilities or developing interventions that could serve as PROSPR follow-on candidates should position their work accordingly.

For biotech companies with longevity pipelines: The PROSPR contract structure creates a template that other federal funders may adopt. Companies with existing clinical data on compounds showing age-related benefits — particularly drugs already approved for other indications — should watch for future ARPA-H solicitations that extend the PROSPR model.

For institutions considering ARPA-H engagement: The contract-not-grant model is ARPA-H's signature. Institutions accustomed to NIH's R-series mechanisms need to build internal capacity for milestone-based reporting, faster decision-making, and the operational tempo that ARPA-H expects. The bureaucratic overhead is different, not less, than traditional grant administration.

For everyone applying for federal health funding: ARPA-H's budget is small relative to NIH — roughly $2.5 billion total versus NIH's $48 billion. But ARPA-H's influence on research direction is disproportionate to its budget. When ARPA-H declares aging a treatable condition and backs it with $144 million in contracts, it signals where the broader federal health research enterprise is likely to move next.

The gap between identifying a promising aging intervention and proving it works in humans has been the field's central bottleneck for decades. PROSPR doesn't solve that problem. But it creates, for the first time, a federally funded pathway through it — and tools like Granted can help researchers track the follow-on opportunities that will emerge as the program's initial results start coming in.